Position within the Organisation
|
|
- Elijah Rice
- 5 years ago
- Views:
Transcription
1 ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September 2016 Review date March 2018 Lead Author(s) Name Joanne Hamilton Dr M Hopkin Minesh Parbat Position within the Organisation Lead Nurse Respiratory DGNHFT GP & Respiratory Lead Prescribing Advisor Presented for discussion, approval and ratification to Core Policies and Procedures Group Change History Version Date Comments 0.1 Oct 09 First draft 0.2 Oct 09 Amended following comments from Pharmaceutical Adviser 0.3 Nov 09 Amended following comments from Core Policies 1 Jan 10 Final ratified edition. 1.1 March 10 Amendment on Theophylline Dosage 12+ Guidelines 1.2 May 10 Amendment on Montelukast micrograms to milligrams(mgs) 1.3 Feb 11 Addition of Fostair to adult guidelines at Step March 11 Change of layout at Step 3 and logos 1.5 January 12 Addition of Seretide 100 Accuhaler at Step 3 asthma
2 treatment guidelines 12 + years guidelines 1.6 January 12 Addition of Seretide 100 Accuhaler at Step 3 asthma treatment guidelines age 5 12 years 2.0 November September 2016 Change of Layout to guidelines Change of Layout to guidelines and treatment options 3.1 June 2017 Draft Updated : Symbicort Smart which is now licensed from the age of 12 years old (previously 18 years old). 4.0 June 2017 Final Ratified edition Updated : Symbicort Smart which is now licensed from the age of 12 years old (previously 18 years old). Link with Care Quality Commission Essential Standards of Quality & Safety Regulation 10, Outcome 16 Assessing & Monitoring the quality of services provision. Regulation13, Outcome 9 Management Of Medicines Link with Trust Purpose and Values statements These guidelines are aimed to improve the health and wellbeing of our local community. They link with values 1-11
3 Summary Sheet These treatment guidelines have been produced as a quick reference guide for HCPs who manage people with Asthma.. The guidelines are based on National Asthma Management Guidelines British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN), These treatment guidelines will help to ensure appropriate, cost effective prescribing for people of all ages, with asthma. The treatment guidelines will form part of an asthma education program. They support HCPs with prescribing and should be used in conjunction with the BTS/SIGN, These guidelines have been widely consulted on since March 2016, including: Dudley Respiratory Group Practice Nurse Mentors Prescribing and Medicines Management Team Presentations to Dudley GPs & Practice Nurses Nurse Consultant These guidelines will be reviewed at least every 2 years or sooner if indicated, by Dudley Respiratory Group or Area Clinical Effectiveness Committee.
4 ASTHMA TREATMENT GUIDELINES Definition: Asthma is a chronic inflammatory respiratory disease. It can affect people of any age, but often starts in childhood. It is characterised by attacks (also known as exacerbations) of breathlessness and wheezing, with the severity and frequency of attacks varying from person to person. The attacks are associated with variable airflow obstruction and inflammation within the lungs, which if left untreated can be life-threatening, however with the appropriate treatment can be reversible CONTROL OF ASTHMA, DEFINED AS: - No daytime symptoms - No limitations on activity including exercise - No night time awakening due to asthma - Normal lung function - No need for rescue medications - No asthma attacks With minimal side effects using the lowest effective doses BEST PRACTICE - Review patients regularly Considering Step Up & Down accordingly - A Spacer device is recommended when using a MDI- - Check Inhaler technique and compliance at each appointment and before starting any additional therapy - Use an in-check device to measure inspiratory effort - The least costly product that is suitable for an individual should be used - Consider total steroid load when reviewing patient - All patients should have a written self-management plan - Reconsider the diagnosis in patients who continue to have symptoms Asthma is not controlled at any step if using SABA: 3 times a week or more: having symptoms 3 times a week or more: waking at least once a week. Regular Inhaled Preventer Inhaled Corticosteroid (ICS) <12yrs Very Low Dose ICS 200mcgs 12yrs Low Dose ICS 400mcgs Initial Add on Therapy <5yrs 5yrs of age (or 6-11yrs >5yrs ADD in a Long Acting B 2 Agonist unable to use a DPI) (LABA) in a combination inhaler
5 ADD Leukotriene Low Dose ICS 6-11yr Very Low Dose ICS + LABA Receptor Antagonist 400mcgs/day in an MDI 200mcgs 12+ Low Dose ICS + LABA 400mcg Review after ONE MONTH <5yrs IF GOOD RESPONSE TO LTRA CONTINUE IF POOR OR NO RESPONSE RECONSIDER DIAGNOSIS REFER TO RESPIRATORY PAEDIATRICIAN 5yrs (or 6-11yrs unable to use a DPI) IF GOOD RESPONSE TO ICS CONTINUE >5yrs IF GOOD RESPONSE TO LABA - CONTINUE IF SOME RESPONSE OR NO RESPONSE THEN GO TO ADDITIONAL ADD ON THERAPY BELOW Additional Add on Therapy SOME RESPONSE to LABA EITHER INCREASE ICS in a combinations inhaler (ICS+LABA) 6-11yrs Low Dose (ICS+LABA) *400mcgs BDP 12+yrs Medium Dose (ICS+LABA) *800/*1000mcgs BDP OR CONTINUE WITH ICS+LABA (in a combination inhaler) and add a LTRA NO RESPONSE TO LABA STOP LABA in a combinations inhaler increase ICS alone (ICS+LABA) and 6 11 years 12+ years Low Dose ICS Medium Dose ICS 400mcgs BDP 800mcgs BDP 5yrs (or 6-11yrs unable to use a DPI) add in a LABA Low Dose ICS 400mcgs BDP (MDI + Spacer) <18yrs REFER TO RESPIRATORY PAEDIATRICIAN 18+ years Consider patients who may be suitable for Maintenance and Reliever therapy SMART/MART >18yrs CONSIDER TRIAL OF LAMA Long Acting Muscarinic Antagonist HIGH DOSE THERAPIES Consider trials of:- Addition of a 4 th drug LTRA
6 LAMA Increasing ICS up to 2000mcgs/day BDP 18+ years Refer to Respiratory Consultant Short Acting B2 Agonist (SABA) Prescribe as required Asthma is not controlled at any step if using SABA: 3 times a week or more: having symptom 3 times a week or more: waking at least once a week KEY: MDI Metered Dose Inhaler SABA Short Acting B 2 Agonist ICS Inhaled Corticosteroids DPI Dry Powder Inhaler BDP Beclometasone LTRA Leukotriene Receptor Antagonist LABA Long Acting B 2 Antagonist LAMA Long Acting Muscarinic Antagonist mcgs micrograms BTS British Thoracic Society SIGN The Scottish Intercollegiate Guidelines Network
7 MAINTENANCE & RELIEVER THERAPY The use of a single inhaler for both maintenance and reliever therapy in asthma Adult patients ( 18 years) use an adequate fixed maintenance dose and additional reliever inhalations of Symbicort/Fostair as required Symbicort 100/6 or 200/6 Turbohaler SMART (12+ years) One inhalation twice a day plus as required OR Two inhalations once daily plus as required OR Two inhalations twice a day plus as required A maximum of 12 inhalations per day (maintenance and reliever): The use of a separate reliever inhaler is NOT required Fostair 100/6 Metered Dose Inhaler MART (18+ years) One inhalation twice a day plus one as required A maximum of 8 inhalations per day (maintenance and reliever): The use of a separate reliever inhaler is NOT required Patients requiring frequent use of rescue inhalations daily should be strongly recommended to seek medical advice. Their asthma should be reassessed and their maintenance therapy should be reconsidered
8 12+ Years Recommended Asthma Treatment Choices - First Line 12 to Brand Name ICS LABA Dosage Regime Total Daily Dose ICS TDD BDP equivalent REGULAR PREVENTER (ICS) Clenil 100 MDI Beclometasone 2 Puffs twice a day 400mcgs = 400mcgs Budesonide 100 Easyhaler Budesonide 1 Puff twice a day 400mcgs = 400mcgs Pulmicort 200 Turbohaler Budesonide 1 Puff twice a day 400mcgs = 400mcgs INITIAL ADD ON THERAPY (ICS+LABA) Symbicort 100/6 Turbohaler Budesonide Formoterol 2 Puffs twice a day 400mcgs = 400mcgs Flutiform 50/5 MDI Fluticasone propionate Formoterol 2 Puffs twice a day 200mcgs = 400mcgs ADDITONAL ADD ON THERAPIES (ICS+LABA) ADDITIONAL ADD ON THERAPIES (ICS) Symbicort 200/6 Turbohaler Budesonide Formoterol 2 Puffs twice a day 800mcgs = 800mcgs Flutiform 125/5 MDI Fluticasone propionate Formoterol 2 Puffs twice a day 500mcgs = 1000mcgs Beclometasone x Fostair 100/6 MDI/Nexthaler Extrafine Formoterol 2 puffs twice a day 400mcgs = 1000mcgs Clenil 200 MDI Beclometasone 2 Puffs twice a day 800mcgs = 800mcgs Budesonide 400 Easyhaler Budesonide 1 Puff twice a day 800mcgs = 800mcgs Pulmicort 400 Turbohaler Budesonide 1 Puff twice a day 800mcgs = 800mcgs HIGH DOSE THERAPY (ICS+LABA) x Flutiform 250/10 MDI Fluticasone propionate Formoterol 2 Puffs twice a day 1000mcgs = 2000mcgs Beclometasone x Fostair 200/6 MDI/Nexthaler Extrafine Formoterol 2 Puffs twice a day 800mcgs = 2000mcgs Low Dose ICS Medium Dose ICS High Dose!CS TDD - Total Daily Dose BDP - Beclometasone ICS - Inhaled Corticosteroid LABA - Long Acting Beta Agonist
9 12+ Years - Other Asthma treatment choices - 2nd Line 12 to Brand Name ICS LABA Dosage Regime Total Daily Dose ICS TDD BDP equivalent REGULAR PREVENTER Qvar 50 MDI Beclometasone Extrafine 2 Puffs twice a day 200mcgs = 500mcgs INITIAL ADD ON THERAPY (ICS + LABA) Seretide 50/25 MDI Fluticasone propionate Salmeterol 2 Puffs twice a day 200mcgs = 400mcgs Seretide 100/50 Accuhaler Fluticasone propionate Salmeterol 1 Puff twice a day 200mcgs = 400mcgs ADDITIONAL ADD ON THERAPIES (ICS+LABA) Seretide 125/25 MDI Fluticasone propionate Salmeterol 2 Puffs twice a day 500mcgs = 1000mcgs Seretide 250/50 Accuhaler Fluticasone propionate Salmeterol 1 Puff twice a day 500mcgs = 1000mcgs ADDITIONAL ADD ON THERAPIES (ICS) Qvar 100 MDI Beclometasone Extrafine 2 Puffs twice a day 400mcgs = 1000mcgs HIGH DOSE THERAPIES (ICS+LABA) Seretide 250/25 MDI Fluticasone propionate Salmeterol 2 Puffs twice a day 1000mcgs = 2000mcgs Seretide 500/50 Accuhaler Fluticasone propionate Salmeterol 1 Puff twice a day 1000mcgs = 2000mcgs Low Dose ICS Medium Dose ICS High Dose!CS TDD - Total Daily Dose BDP - Beclometasone ICS - Inhaled Corticosteroid LABA - Long Acting Beta Agonist
10 <12 Years Asthma Inhaler Treatment Choices REGULAR PREVENTER INITIAL ADD ON PREVENTER (ICS + LABA) Total Daily TDD BDP <5 5 to 11 Brand Name ICS LABA Dosage Regime Dose ICS equivalent Clenil 50 MD! Beclometasone 2 Puffs twice a day 200mcgs = 200mcgs Pulmicort 100 Turbohaler Budesonide 1 Puff twice a day 200mcgs = 200mcgs 6+ Budesonide 100 Easyhaler Budesonide 1 Puff twice a day 200mcgs = 200mcgs 6+ Symbicort 100/6 Turbohaler Budesonide Formoterol 1 Puff twice a day 200mcgs = 200mcgs If 5years of age or 6-11yrs and unable to use Dry Powder Inhaler (Turbohaler) then: Clenil 100 MDI Beclometasone 2 puffs twice a day 400mcgs = 400mcgs ADDITIONAL ADD ON THERAPIES (ICS + LABA) 6+ Symbicort 100/6 Turbohaler Budesonide Formoterol 2 Puffs twice a day 400mcgs = 400mcgs Seretide 50/25 MDI Fluticasone propionate Salmeterol 2 Puffs twice a day 200mcgs = 400mcgs ADDITIONAL ADD ON THERAPIES (ICS) Clenil 100 MDI Beclometasone 2 Puffs twice a day 400mcgs = 400mcgs 6+ Budesonide 100 Easyhaler Budesonide 2 Puffs twice a day 400mcgs = 400mcgs Pulmicort 200 Turbohaler Budesonide 1 Puff twice a day 400mcgs = 400mcgs Flixotide 50 MDI Fluticasone 2 Puffs twice a day 200mcgs = 400mcgs HIGH DOSE THERAPIES (ICS + LABA) Clenil 100 Beclometasone 4 Puffs twice a day 800mcgs = 800mcgs Seretide 125/25 MDI Fluticasone propionate Salmeterol 2 Puffs twice a day 500mcgs = 1000mcgs Very low dose ICS Low Dose ICS Medium Dose ICS TDD - Total Daily Dose BDP - Beclometasone ICS - Inhaled Corticosteroid LABA - Long Acting Beta Agonist
11 SABA Short Acting B 2 Antagonist Short Acting Bronchodilators 12 to <5 5 to Brand Name SABA Dosing Regime 2 puffs as required up to a max of 4 times a Ventolin 100mcgs MDI Salbutamol day 2 puffs as required up to a max of 4 times a day Salamol Easibreathe 100mcgs MDI Salbutamol Bricanyl Turbohaler 500mcgs Terbutaline 1 puff as required up to a max of 4 times a day 2 puffs as required up to a max of 4 times a Salbutamol Easyhaler 100mcgs Salbutamol day NOTE: Asthma is not controlled at any step if using SABA: 3 times a week or more: having symptoms 3 times a week or more: waking at least once a week. LAMA Long Acting Muscarinic Antagonist Long Acting Muscarinic Antagonists (LAMA) 18+ Brand Name LAMA Dosage Regime Spiriva Respimat 2.5 micrograms Tiotropium 2 Puffs once daily (This is indicated as an add on bronchodilator treatment in adult patients with asthma who are currently treated with a maintenance combination inhaler (ICS+LABA) at 800mcgs/day BDP equivalent and who experienced one or more severe exacerbations in the previous year)
12 Leukotriene Receptor Antagonists (LTRA) 6 months to 5 years Once daily at night 6-14 years Once daily at night 15+ years Once daily at night LTRA - Leukotriene Receptor Antagonist Montelukast 4mg Chewtab or 4mg granules (do not mix with fluid but can be mixed with food) Montelukast 5mg Chewtab Montelukast 10mg tablet SPACER DEVICES Wash your spacer once a month using detergent, such as washing-up liquid. Don t scrub the inside of the spacer as this affects the way it works. Leave it to air-dry as this helps to prevent the medicine sticking to the sides of the chamber and reduces static Wipe the mouthpiece clean of detergent before you use it again. Don t worry if your spacer looks cloudy - that doesn t mean its dirty Your spacer should be replaced at least every year, especially if you use it daily, but some may need to be replaced sooner - ask your GP, asthma nurse or pharmacist if you re unsure Ensure the inhaler is compatible with the spacer device Aerochamber Infant Device with Mask (Orange) 0-18 months Aerochamber Child Device with Mask (yellow) 1 year 5 years Aerochamber plus with Mask (Blue) 5+ years Volumatic with Facemask 0+ years Volumatic 3+ years Aerochamber Plus (Blue) 5+ years
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationAdult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationMedicines Management of Asthma
Wandsworth Borough Team Medicines Management of Guidelines for Primary Care September 2011 Version 1 Guideline Authors: Shaneez Dhanji (Wandsworth borough) Reena Rabheru-Dodhy (Sutton & Merton borough)
More informationASTHMA TREATMENT GUIDE (ADULTS)
ASTHMA TREATMENT GUIDE (ADULTS) The BTS/SIGN guideline provides a wide range of information and guidance on the treatment of patients with asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/
More informationProgress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG
Progress, Paediatrics and Protocols Dr Andy Powell Dr Lesley Ayling West Hampshire CCG Progress Solutions CQUIN discharge bundle (including personal action plan), specialist review, immediate management
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationDiagnosis and management of Asthma in Adults. (Version 1.1)
Pan-Birmingham Respiratory Clinical Network Diagnosis and management of Asthma in Adults (Version 1.1) Revision History Guideline Author: Guideline Sponsor: Date of Approval: 23/03/2017 Approved by: Date
More informationMedicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationAsthma Guidelines and Pharmacological Treatment. Dr James Wilkinson
Asthma Guidelines and Pharmacological Treatment Dr James Wilkinson Asthma is a common disease in the UK 5.4 million people in the UK are currently receiving treatment for asthma: 4.3 million adults (1
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationTreatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service
Treatment choices for patients with asthma or COPD Jo Riley Lead Nurse For Oxfordshire Respiratory Service What is the difference? Is it all about? Inhaled steroids Long acting ß2 agonists Short acting
More informationbeclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))
Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationNancy Davis, RRT, AE-C
Nancy Davis, RRT, AE-C Asthma Statistics 25.6 million Americans diagnosed with asthma 6.8 million are children 10.5 million missed school days per year 14.2 lost work days for adults Approximately 10%
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationInhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years. Issue date: November 2007
Issue date: November 2007 Review date: November 2012 Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years NICE technology appraisal guidance 131 NICE technology
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationPocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals
Pocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals Endorsed by NHSGGC Respiratory Managed Clinical Network; June 2016 Designed by Medical Illustration Services Contents
More informationPATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet
PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet What is COPD? COPD is a general term, which includes the conditions chronic asthma, chronic bronchitis and emphysema. It is due
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationAsthma - An update BTS Asthma Guidelines 2016
Asthma - An update BTS Asthma Guidelines 2016 Dr Ian Clifton Overview Diagnosis Supported self-management Non-pharmacological management Drugs / inhaled therapy Difficult asthma services Case discussions
More informationAsthma and the competitive swimmer
Asthma and the competitive swimmer Introduction: One in seven children and one in 25 adults in Great Britain have asthma and the number is growing. Thus every swim squad or club will have a number of asthmatics
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationSeretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.
Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationTechnology appraisal guidance Published: 28 November 2007 nice.org.uk/guidance/ta131
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years Technology appraisal guidance Published: 28 November 2007 nice.org.uk/guidance/ta131 NICE 2018. All rights
More informationSAMPLE. mg by mouth every day for day(s) Prednisolone. Other Medicine: Medicine Dose How long Directions
Pediatric Asthma Discharge Prescription and Short-Term Plan The doctor will fill out this form before your child is discharged. Please follow this plan until you see your usual doctor in 3 to 7 days. Hospital
More informationPlease also see section on Drugs used in substance dependence for patients with established chemical dependence
Respiratory System Algorithm for the selection of the most appropriate inhaler device for patients with chronic stable asthma Information on Inhaler devices Devices β 2 agonist bronchodilators Antimuscarinic
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationBulletin Independent prescribing information for NHS Wales
Bulletin Independent prescribing information for NHS Wales Respiratory disease September 2014 Respiratory diseases account for one in seven of all deaths in Wales the third largest cause of mortality for
More information500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device
3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose
More informationAllwin Mercer Dr Andrew Zurek
Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationRESPIRATORY INHALERS
RESPIRATORY INHALERS The correct administration of inhaled therapy is essential for successful, cost-effective and safe therapy. Everyone, including the patient needs to understand the importance of ensuring
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationInformation for you Asthma Information
Information for you Asthma Information Follow us on Twitter @NHSaaa Find us on Facebook at www.facebook.com/nhsaaa Visit our website: www.nhsaaa.net All our publications are available in other formats
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2013, Updated September 2013 Review date: September 2016 Bulletin 176 : Choice of Inhaled Corticosteroid / Long Acting Beta 2 Agonist (ICS/LABA)
More informationAustralian Asthma Handbook. Key table and figures Version 1.2
Australian Asthma Handbook Key table and figures Version 1.2 DIAGNOSIS OF ASTHMA Figure. Steps in the diagnosis of asthma in adults Table. Findings that increase or decrease the probability of asthma in
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationGetting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital
Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com } Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate)
More informationInformation for Parents and Young People on New and Emerging Treatments in Asthma
Information for Parents and Young People on New and Emerging Treatments in Asthma Asthma continues to be a very common condition that causes a lot of distress to children and their families. For some it
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationcontrol in the lowest dose providing adequate Maintain high dose ICS Use daily steroid tablet dose Consider trials of: Increasing ICS up to
Summary of management in adults sthma - suspected dult asthma - diagnosed Diagnosis and ssessment Evaluation: assess symptoms, measure lung function, check inhaler technique and adherence adjust dose update
More informationDelivering Aerosol Medication in ICU
Delivering Aerosol Medication in ICU 18th Aug 2017 Lau Chee Lan Pharmacist HCTM PPUKM ASMIC 2017 Aerosol Therapy Part of the treatment for a variety of respiratory disease * asthma and chronic obstructive
More informationAWMSG SECRETARIAT ASSESSMENT REPORT
AWMSG SECRETARIAT ASSESSMENT REPORT Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta ) inhalation powder, 184/22 inhalation powder Reference number: 1216 FULL SUBMISSION This report has
More informationAsthma in Pregnancy. Asthma. Chronic Airway Inflammation. Objective Measures of Airflow. Peak exp. flow rate (PEFR)
Chronic Airway Inflammation Asthma in Pregnancy Robin Field, MD Maternal Fetal Medicine Kaiser Permanente San Francisco Asthma Chronic airway inflammation increased airway responsiveness to a variety of
More informationInhalation devices, proper technique and cleaning
Preventing Your Symptoms and Taking Your Medications Inhalation devices, proper technique and cleaning Knowing how to use your medications properly is important because inhaled drugs are meant to get directly
More informationASTH MA BOOK 2. September 2012 FP117/2 CENTRE FOR PHARMACY POSTGRADUATE EDUCATION
A F O C A L P O I N T L E A R N I N G P R O G R A M M E ASTH MA S E C O N D E D I T I O N BOOK 2 September 2012 FP117/2 CENTRE FOR PHARMACY POSTGRADUATE EDUCATION Content contributor Anna Murphy, consultant
More information